Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 635

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 635
---
 within 60 days of June 30, 2025 (assuming approval of the Option Exchange Proposal and closing of the Business Combination). |

| (6) | Jiandong (Peter) Xu is the manager and controlling member of the Sponsor. As such, each of the Sponsor and Mr. Xu may be deemed to share beneficial ownership of the ordinary shares held directly by the Sponsor. Mr. Xu disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, and disclaims any beneficial ownership of such shares other than to the extent of any pecuniary interest each may have therein, directly or indirectly. The business address of the Sponsor is 437 Madison Avenue, 27th Floor, New York, New York 10022. |

| (7) | Consists of shares issuable upon separation of the Denali Private Placement Units which will automatically occur at Closing. |

| (8) | Consists solely of founder shares. |

| (9) | Consists of (i) 1,432,500 shares of New Semnur Common Stock based on the Exchange Ratio, (ii) 510,000 shares of New Semnur Common Stock issued upon the automatic separation of the Denali Private Placement Units into its component parts upon Closing and (iii) 167,337 shares of New Semnur Common Stock issued upon the assumed conversion of the Working Capital Loans in connection with Closing. |

| (10) | The business address of Scilex is 960 San Antonio Road, Palo Alto, CA 94303. |

| (11) | Consists of (i) 200,000,000 shares of New Semnur Common Stock issued as Merger Consideration, (ii) 600,000 shares of New Semnur Common Stock issued as Preferred Consideration, (iii) 18,000 shares of New Semnur Common Stock issued upon the assumed conversion of the Scilex Convertible Note in connection with Closing, which is the maximum number of shares that may be issued upon the conversion of the Scilex Convertible Note, and (iv) 500,000 shares of New Semnur Common Stock issued in exchange for 500,000 shares of Denali Ordinary Shares upon Closing. |

| (12) | This information is based solely on a Schedule 13G filed by Mizuho Financial Group, Inc. (“Mizuho”) with the SEC on February 14, 2023. Mizuho has sole voting power of